Phase III Lot Consistency Trial
Research payments
$2,326,331
Through program year 2020, $2,326,331 in research payments was reported against Phase III Lot Consistency Trial, across 364 payments, paid by Pfizer Inc..
- Paid by
- Pfizer Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $36,740 | 12 |
| 2019 | Research | $2,289,591 | 352 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Shane Christensen Salt Lake City, UT Named on 17 payments
- Bruce Rankin Deland, FL Named on 17 payments
- Kevin Cannon Wilmington, NC Named on 17 payments
- Jeffrey Rosen Coral Gables, FL Named on 16 payments
- Keith Vrbicky Norfolk, NE Named on 16 payments
- Mark Turner Meridian, ID Named on 16 payments
- Jamshid Saleh Redding, CA Named on 16 payments
- Harry Studdard Mobile, AL Named on 16 payments
- James Peterson Salt Lake City, UT Named on 16 payments
- Howard Schwartz Hollywood, FL Named on 16 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.